All Stories

  1. Healthcare costs and outcomes associated with laboratory-confirmed Lyme disease in Ontario, Canada: A population-based cohort study
  2. SARS-CoV-2 mitochondriopathy in COVID-19 pneumonia exacerbates hypoxemia
  3. Trends in Clostridioides difficile infection rates in Canadian hospitals during the coronavirus disease 2019 (COVID-19) pandemic
  4. Characterization of Healthcare-Associated and Community-Associated Clostridioides difficile Infections among Adults, Canada, 2015–2019
  5. 2021–2022 AMMI Canada guidance on the use of antiviral drugs for influenza in the COVID-19 pandemic setting in Canada
  6. Low yield of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) asymptomatic routine screen testing, despite high community incidence
  7. Phylogenomics reveals viral sources, transmission, and potential superinfection in early-stage COVID-19 patients in Ontario, Canada
  8. The pitfalls of mass hospital health care worker testing for COVID-19
  9. Guidance on the use of antiviral agents for the 2019–2020 influenza season
  10. COVID-19 and cancer: do we really know what we think we know?
  11. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic
  12. Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016
  13. Long-Term Sequelae and Health-Related Quality of Life Associated With Lyme Disease: A Systematic Review
  14. Use of antiviral drugs for seasonal influenza: Foundation document for practitioners—Update 2019
  15. Estimating direct healthcare costs attributable to laboratory‐confirmed Lyme disease in Ontario, Canada: A population‐based matched cohort study using health administrative data
  16. Combined treatment methods are needed to treat a rare lung infection.
  17. Human granulocytic anaplasmosis acquired from a blacklegged tick in Ontario
  18. A Longitudinal Four-year Pre-Post Intervention Study Evaluating the Use of an Antimicrobial Stewardship Application
  19. Longitudinal Multicenter Analysis of Outcomes After Cessation of Control Measures for Vancomycin-Resistant Enterococci
  20. Sexual behaviors among women living with HIV in Ontario, Canada
  21. Burden and risk factors for gastrointestinal symptom distress in HIV patients in the modern antiretroviral era
  22. Adequacy of Mental Health Services for HIV-Positive Patients with Depression: Ontario HIV Treatment Network Cohort Study
  23. Assessing the magnitude and trends in hospital acquired infections in Canadian hospitals through sequential point prevalence surveys
  24. Lyme disease: How reliable are serologic results?
  25. High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada
  26. Comparison of coping strategies and supports between aboriginal and non-aboriginal people living with HIV in Ontario
  27. Guidance for Practitioners on the Use of Antiviral Drugs to Control Influenza Outbreaks in Long-Term Care Facilities in Canada, 2014-2015 Season
  28. Guidance on The Use of Antiviral Drugs for Influenza in Acute Care Facilities in Canada, 2014-2015
  29. The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare Diseases
  30. Toward a Functional Definition of a “Rare Disease” for Regulatory Authorities and Funding Agencies
  31. Application of a Policy Framework for the Public Funding of Drugs for Rare Diseases
  32. Opportunity Cost of Funding Drugs for Rare Diseases
  33. The Vioxx® legacy: Enduring lessons from the not so distant past
  34. Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
  35. A confusing Case –Weissella confusaProsthetic Joint Infection: A Case Report and Review of the Literature
  36. Renal Failure, Hepatitis and Myocarditis in A Previously Healthy Man
  37. Microbial source tracking and spatial analysis of E. coli contaminated private well waters in southeastern Ontario
  38. The Velvet Myocardium: Potential Harbinger of Death in Acute Myocarditis?
  39. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009
  40. Application of Operations Research to Funding Decisions for Treatments with Rare Disease
  41. Emergency Department Surveillance as a Proxy For The Prediction of Circulating Respiratory Viral Disease in Eastern Ontario
  42. An Evaluation Framework for Funding Drugs for Rare Diseases
  43. Acute orbital inflammatory syndrome following H1N1 immunization
  44. Canadian clinical practice guidelines for acute and chronic rhinosinusitis
  45. Canadian Practice Guidelines for Surgical Intra-Abdominal Infections
  46. Health technology assessment: A comprehensive framework for evidence-based recommendations in Ontario
  47. Clinical Practice Guidelines for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults
  48. Impact of a Fluoroquinolone Restriction Policy in an Elderly Population
  49. RETIRED: Canadian Consensus Guidelines on Human Papillomavirus
  50. Laboratory diagnosis of human infection with avian influenza
  51. Complicated Urinary Tract Infection in Adults
  52. HYPERSENSITIVITY REACTION ASSOCIATED WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR INTERSTITIAL CYSTITIS
  53. The Management of Infection and Colonization due to Methicillin-ResistantStaphylococcus aureus: A CIDS/CAMM Position Paper
  54. Infection Control for the Otolaryngologist in the Era of Severe Acute Respiratory Syndrome
  55. The oxazolidinones
  56. Macrolides: A Canadian Infectious Disease Society Position Paper
  57. Antimicrobial Regimens Prescribed by Canadian Physicians for Chemotherapy-Induced Febrile Neutropenic Episodes
  58. Oral histoplasmosis masquerading as an invasive carcinoma
  59. Growth of Coagulase Negative Staphylococci in Peritoneal Dialysate Fluid
  60. Clostridium sordellii infection and toxin neutralization
  61. Mutation of Host Cell Determinants which Discriminate between Lytic and Persistent Mouse Hepatitis Virus Infection Results in a Fusion-resistant Phenotype
  62. Factitious AIDS